- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07454525
Examine Impact of Topical Application of Active Versus Placebo on the Skin Microbiome in Sensitive Skin. (SkinBiome)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This interventional, prospective clinical study aims to investigate the effects of topical application of two facial creams-one placebo and one containing active postbiotics (from Bifidobacterium and Pediococcus genera)-on the skin microbiome and appearance in women with sensitive skin and high sun exposure. The study is conducted remotely over a 14-week period and involves self-collection of skin microbiome samples and headshot photographs using the Haut AI application.
The primary objective is to identify changes in the skin microbiome and visual skin characteristics following the use of a placebo cream (Product A) for 6 weeks and an active cream (Product B) for 8 weeks. Secondary objectives include exploring the temporal dynamics of the microbiome, assessing self-perceived effects of the products, and documenting changes in skin appearance.
Participants are 30 women aged 40 to 60, residing in mid to west coast regions of the United States, representing all ethnicities and Fitzpatrick skin types. Eligible participants must have self-assessed sensitive skin (SS10 > 13), mild to moderate fine lines and wrinkles, and spend at least one hour outdoors under high sun exposure (10am-4pm) five times per week. They must be willing to replace their current skincare routine with the study regimen and maintain their lifestyle and diet throughout the study.
Exclusion criteria include prior use of the study products within the past three months, participation in similar studies within the last 30 days, active skin disorders, recent use of antibiotics, NSAIDs, corticosteroids, or hormone treatments, pregnancy or breastfeeding, and any medical conditions or procedures that could affect skin appearance. Participants must also demonstrate reliability and willingness to follow the study protocol.
The study design includes four microbiome sampling timepoints: after 2 weeks of placebo use (T0), at the end of the placebo phase (week 6, T1), after 4 weeks of active product use (week 10, T2), and at the end of the active phase (week 14, T3). At each timepoint, participants will collect a skin swab from the forehead and submit a headshot photo via the Haut AI app. A baseline photo is also collected before starting the regimen. They will also answer a questionnaire to assess the self-perceived evolution.
Each participant receives a study kit containing both products and four microbiome sampling kits. Participants will be instructed to apply 1 mL of product twice a day. Samples are returned to HelloBiome or directly to the lab for sequencing. Microbiome analysis is performed using 16S rRNA and ITS sequencing to detect bacterial and fungal communities. Data are processed and analyzed by HelloBiome using bioinformatics tools to assess microbial load, diversity, and composition.
Statistical analysis includes parametric and non-parametric tests (e.g., t-test, ANOVA, Mann-Whitney, Kruskal-Wallis, Wilcoxon signed-rank) and PERMANOVA for microbiome compositional data. Samples not meeting quality thresholds may be excluded from final analysis.
Data management ensures participant confidentiality through anonymization and secure storage on specific servers. Safety will be evaluated through the documentation of all adverse events.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nuria Gispets, MSc
- Phone Number: +34 607026612
- Email: gispets@ab-biotics.com
Study Contact Backup
- Name: Maria Rodriguez-Palmero, PhD
- Phone Number: +34 638679157
- Email: rodriguezpalmero@ab-biotics.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 40-60 among all ethnicities and Fitzpatrick scale.
- With self-assessed sensitive skin (SS10 > 13) and self-reported mild to moderate fine lines and wrinkles.
- Must spend minimum 1 hour outside from 10am-4pm at least 5 times per week.
- Residing within the same country on the mid to west coast (California, Nevada, Utah, Arizona, Colorado, New Mexico, Kansas, Oklahoma, Texas, Illinois, Kansas, Idaho, Nebraska, Montana).
- Consider themselves to be in good health.
- Willing to continue to use their current cosmetic products (foundation, blush, eyeshadow, sunscreen, etc.) and with the same routine/frequency if they do not contain anti-aging ingredients.
- Willing to refrain from using AHA, other peeling acids (PHA, BHA), prescription products such as retinoids or hydroquinone etc. during the study.
- Willing to take skin swabs to support measures of the skin microbiome.
- Must understand their role in the study, provide written informed consent, and fully participate over the 14-week period.
- Willing to use the products provided within the study as instructed. Willing to change their current skincare routine and replace it with the given regimen for 14 weeks.
- Willing to maintain diet and lifestyle (including physical exercise) during study period.
Exclusion Criteria:
- Used any of the products to be tested in the claim study in the past 3 months. - Participation in a similar skin study within the past 30 days.
- Have active skin disorders such as psoriasis, eczema, allergies, wounds, scars, or severe acne on their forehead.
- Regular use of probiotic supplements
- Consumption of fermented foods (including kefir, probiotic containing yoghurt, kombucha or other) for more than 5 times a week
- Are orally or topically using or have used in the past 6 months: antibiotics, NSAIDS, antihistamines, immuno-suppressants, corticosteroids, prescription products such as retinoids, hydroquinone, or strong AHA treatments.
- Have started hormonal treatment (e.g., contraceptives, fertility treatments, or HRT for menopause) within the past 3 months or in case they are on a treatment for more than 3 months they are unwilling to maintain a stable regimen for the duration of the study.
- Pregnant or breastfeeding.
- Any history of significant disease or medical condition to alter skin appearances such as type 2 diabetes, cancer, renal disorders or hepatic dysfunction.
- Individuals who have had medical procedures in their face such as laser resurfacing (or any type of laser treatment ex. photo depilation), plastic surgery (including Botox) within the last 12 months or history of UV radiation (tanning and facial lamps) within the last 3 months.
- Active Vitiligo or any other chronic skin conditions.
- Individuals with any history that, in the investigator's opinion, indicates potential harm to the subject or could jeopardize the validity of the study.
- History of poor cooperation, non-compliance, unreliability, or unwillingness to follow the research protocol and timeline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Study Arm
All patients will receive both products in a sequential manner.
First 6 weeks of placebo base cream followed by 8 weeks of active cream.
|
Active facial cream with postbiotics from Bifidobacterium and Pediococcus genera.
Product will be applied to the face twice a day in the morning and evening
Placebo facial cream without postbiotics with same other ingredients as active product.
Product will be applied to the face twice a day in the morning and evening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Microbiome
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Changes in the skin microbiome composition.
Composition will be evaluated by using next-generation sequencing (NGS) through a total of 14-weeks usage of placebo (Product A - base formulation) for 6 weeks and active (Product B - Base formulation + active postbiotics) for 8 weeks in middle aged older women with sensitive skin with high sun exposure.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Change in skin appearance
Time Frame: Baseline (week 2); Week 6, Week 10, Week 14
|
Change in skin appearance based on headshot photo taken by the Haut AI application.
Evolution of skin parameters will be evaluated; A total score will be calculated by summing total scores of: Eye bags, Hydration, Lines, Pigmentation, Pores, Redness, Translucency and Uniformness.
All of them get a score of 0-100, therefore we will get a total score of 0-800.
|
Baseline (week 2); Week 6, Week 10, Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-perceived impact on skin characteristics.
Time Frame: Baseline (week 2), Week 6, Week 10, Week 14
|
Characterize self perceived positive or negative impacts of routine facial cream usage comparing between placebo and active in middle aged women with skin sensitivity along with high sun exposure.
Patients will complete the SS10 questionnaire designed to capture self perceived changes as well as other custom questions.
|
Baseline (week 2), Week 6, Week 10, Week 14
|
|
Eye bags / Eye area condition
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Eye bags / Eye area condition based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Hydration
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Hydration based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Lines
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Lines based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Pigmentation
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Pigmentation based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Pores
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Pores based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Redness
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Redness based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Translucency
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Translucency based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Uniformness
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Uniformness based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Acne
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Acne based on headshot photo taken by the Haut AI application.
A total score will be recolected using a score of 0-100.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Skin Type
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Skin type based on headshot photo taken by the Haut AI application.
It reflects how facial skin responds to internal and environmental factors, which may cause shifts between types like normal, oily, dry, and combination.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Skin tone
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Skin tone based on headshot photo taken by the Haut AI application.
Skintone Classification algorithm analyses how tan the skin is and returns the result as one of the 6 values: Very light, Light, Intermediate, Tan, Brown, Dark.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Perceived Age
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Perceived Age based on headshot photo taken by the Haut AI application.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
ITA score
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in ITA score based on headshot photo taken by the Haut AI application.
Quantifies skin color using CIELAB color space.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
|
Eye Age
Time Frame: Baseline (week 2), Week 6, Week 10 and Week 14
|
Change in Eye Age based on headshot photo taken by the Haut AI application.
based on the part of the face that is most prone to the aging process: the areas around the eyes.
Eye age reflects the pace of aging.
|
Baseline (week 2), Week 6, Week 10 and Week 14
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2025 KN102025 / Skinbiome
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin
-
University Hospital, BrestCardiff University; Karolinska Institutet; Lund University; University of Bergen; University Hospital Muenster and other collaboratorsNot yet recruitingSkin Condition | Skin Disease | Skin Disorder | Inflammatory Skin Conditions | Autoimmune Skin Diseases | Cancerous Skin Conditions | Genetic Skin ConditionsFrance
-
PharmanexCompletedSkin Elasticity | Beauty Drink Powder | Cosmetic Apparatus on Skin | Skin Dryness | Skin Moisture | Skin Evenness | Skin FirmnessChina
-
Vichy LaboratoiresCPCAD GIE; SKINPHARMANot yet recruitingSkin Elasticity | Skin Evenness | Skin Firmness | Wrinkles and Folds in Lower Face | Skin Ageing | Skin Smoothness | Visible Skin Aging Signs | Skin Radiance | Skin Density
-
TCI Co., Ltd.Active, not recruitingSkin Condition | Skin Hydration | Anti Skin AgingTaiwan
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Skin Neoplasm | Skin Disorder | Skin NeoplasmUnited States
-
ESM Technologies, LLCPrinceton Consumer Research CorporationEnrolling by invitation
-
Eurofarma Laboratorios S.A.CompletedSkin Lesion | Skin Care | Skin LesionsBrazil
-
Istanbul Medipol University HospitalMedipol University; Kartal Dr. Lütfi Kirdar City HospitalRecruitingPressure Injury | Skin Lesions | Skin InjuryTurkey (Türkiye)
-
Hungkuang UniversityCompletedSkin Elasticity | Skin Hydration | Skin Wrinkles | Skin Quality | Melanin Hyperpigmentation | Skin RednessTaiwan
-
Shanghai EGT Synbio Group Co., Ltd.Completed
Clinical Trials on Active Cream
-
Amazentis SAproDERM GmbHCompleted
-
Amazentis SAproDERM GmbHCompletedErythema | Skin Inflammation | Sun Damaged SkinGermany
-
AB Biotics, SADr. Goya Análisis, SL.Not yet recruitingSkin | Face Skin Photoaging | Fine Lines | Face Aging/Photo Aging of Moderate Grade | Skin Ageing
-
Santalis Pharmaceuticals, Inc.ClinDatrix, Inc.; Fremantle DermatologyWithdrawn
-
Medinova AGCompletedPhlebitis | ThrombophlebitisThailand
-
University of West AtticaCompleted
-
CDA Research Group, Inc.Completed
-
Arcutis Biotherapeutics, Inc.TerminatedVitiligoUnited States
-
Huashan HospitalCompleted
-
University of NebraskaTeva Branded Pharmaceutical Products R&D, Inc.WithdrawnMultiple SclerosisUnited States